Par Drugs And Chemicals credit ratios

·UnclassifiedChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
−41.8−41.8−27.6−36.7−22.2
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−0.37×−0.37×−0.28×−0.43×−0.31×
−2.28×−2.44×−1.41×−1.61×−1.22×
105.48×105.48×193.11×180.97×112.42×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

PAR₹120.70

Par Drugs And Chemicals Limited

· Unclassified
₹ CrorePeersBALAXICROWNSTEELCITYHINDCONLATTEYSHECPROJECTAIROLAMGROBTEAMcap ₹149 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Net Debt-22.2-36.7-27.6-41.8-41.8
Net Debt/Equity-0.31-0.43-0.28-0.37-0.37
Net Debt/EBITDA-1.22-1.61-1.41-2.44-2.28
Interest Coverage (EBIT/Interest)112.42180.97193.11105.48105.48
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.